Laurent Dercle
Columbia University Medical Center
131 Papers
126 Citations
Laurent Dercle is an academic researcher from Columbia University Medical Center. The author has contributed to research in topics: Medicine & Internal medicine. The author has an hindex of 25, co-authored 96 publications. Previous affiliations of Laurent Dercle include NewYork–Presbyterian Hospital & Institut Gustave Roussy.
Chat about Author
Papers
Hyperprogressive Disease Is a New Pattern of Progression in Cancer Patients Treated by Anti-PD-1/PD-L1.
Stéphane Champiat,Stéphane Champiat,Laurent Dercle,Samy Ammari,Christophe Massard,Antoine Hollebecque,Sophie Postel-Vinay,Sophie Postel-Vinay,Nathalie Chaput,Alexander M.M. Eggermont,Aurélien Marabelle,Aurélien Marabelle,Jean-Charles Soria,Jean-Charles Soria,Charles Ferté,Charles Ferté +15 more
TL;DR: A novel aggressive pattern of hyperprogressive disease or HPD exists in a fraction of patients treated with anti-PD-1/PD-L1 monotherapy, and this observation raises some concerns about treating elderly patients (>65 years old), and suggests further study of this phenomenon.
1.1K
A radiomics approach to assess tumour-infiltrating CD8 cells and response to anti-PD-1 or anti-PD-L1 immunotherapy: an imaging biomarker, retrospective multicohort study
Roger Sun,Roger Sun,Elaine Johanna Limkin,Elaine Johanna Limkin,Maria Vakalopoulou,Maria Vakalopoulou,Laurent Dercle,Laurent Dercle,Stéphane Champiat,Shan Rong Han,Loic Verlingue,David Brandao,Andrea Lancia,Andrea Lancia,Andrea Lancia,Samy Ammari,Antoine Hollebecque,Jean-Yves Scoazec,Jean-Yves Scoazec,Aurélien Marabelle,Christophe Massard,Jean-Charles Soria,Jean-Charles Soria,Charlotte Robert,Nikos Paragios,Nikos Paragios,Eric Deutsch,Charles Ferté,Charles Ferté +28 more
TL;DR: A radiomic signature predictive of immunotherapy response by combining contrast-enhanced CT images and RNA-seq genomic data from tumour biopsies to assess CD8 cell tumour infiltration was developed and validated.
1K
Promises and challenges for the implementation of computational medical imaging (radiomics) in oncology.
Elaine Johanna Limkin,Roger Sun,Roger Sun,Laurent Dercle,Evangelia I. Zacharaki,Charlotte Robert,Charlotte Robert,Sylvain Reuzé,Sylvain Reuzé,Antoine Schernberg,Antoine Schernberg,Nikos Paragios,Eric Deutsch,Charles Ferté +13 more
TL;DR: This Review addresses the critical issues to ensure the proper development of radiomics as a biomarker and facilitate its implementation in clinical practice.
672
Identification of Non-Small Cell Lung Cancer Sensitive to Systemic Cancer Therapies Using Radiomics
Laurent Dercle,Laurent Dercle,Matthew Fronheiser,Lin Lu,Shuyan Du,Wendy Hayes,David Leung,Amit Roy,Julia Wilkerson,Pingzhen Guo,Antonio Tito Fojo,Lawrence H. Schwartz,Binsheng Zhao +12 more
TL;DR: Using standard-of-care CT images obtained from patients with a diagnosis of non–small cell lung cancer, radiomics signatures predicting the sensitivity of tumors to nivolumab, docetaxel, and gefitinib were defined.
Diagnostic Performance of 4D CT and Sestamibi SPECT/CT in Localizing Parathyroid Adenomas in Primary Hyperparathyroidism.
Randy Yeh,Yu-Kwang Donovan Tay,Gaia Tabacco,Laurent Dercle,Jennifer H Kuo,Leonardo Bandeira,Catherine McManus,David Leung,James A. Lee,John P. Bilezikian +9 more
TL;DR: Four-dimensionalCT provided superior preoperative localization compared with sestamibi SPECT/CT in patients with single and multigland disease, and the combination of the two modalities did not improve diagnostic performance compared with four-dimensional CT alone.
125